Literature DB >> 15214625

Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances.

D Eric Brush1, Steven B Bird, Edward W Boyer.   

Abstract

The Internet may represent a new mechanism by which adolescents initiate the use of illicit substances. The existence of multiple partisan websites providing misinformation regarding the safety of these substances may lead to an increase in unsafe behavior among this age group. Adverse outcomes related to Internet-based drug information are rarely identified. We report a case of an adolescent whose use of the Internet to obtain drug information led to severe poisoning from the combination of a monoamine oxidase inhibitor, harmaline, and a hallucinogenic tryptamine, 5-methoxydimethyltryptamine (5-MeO-DMT).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15214625     DOI: 10.1081/clt-120030949

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  21 in total

1.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

2.  Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Bioanalysis       Date:  2009-04       Impact factor: 2.681

3.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

4.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

5.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Authors:  Hong-Wu Shen; Chao Wu; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

6.  Nonlinear pharmacokinetics of 5-methoxy-N,N-dimethyltryptamine in mice.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2011-04-04       Impact factor: 3.922

Review 7.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

8.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

Authors:  Chao Wu; Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2009-05-13       Impact factor: 5.858

9.  Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2013-02-07       Impact factor: 3.922

10.  Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.

Authors:  Adam L Halberstadt; Mahalah R Buell; Virginia L Masten; Victoria B Risbrough; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2008-07-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.